Evidence map›Paper›PMID 35904045›Full record

ArticleCNS spectrums2023

Open innovation: the key to advancing brain health.

Harris A Eyre, Jason Searfoss, Malcolm Hopwood, Michael Berk, Shuo Chen, Jeffrey Cummings, Francois Veron, Vicki Zikopoulou, Agustin Ibanez, Kacie Kelly and 3 more

Abstract readEditorial
In one paragraph

Article in CNS spectrums, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Harris A EyreNeuroscience-Inspired Policy Initiative, Organisation for Economic Co-Operation and Development and the PRODEO Institute, Paris, France.ORCID 0000-0003-4827-8258
Jason SearfossBoomtown Accelerators, Boulder, CO, USA.
Malcolm HopwoodDepartment of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
Michael BerkInstitute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, VIC, Australia.
Shuo ChenNeuroscience-Inspired Policy Initiative, Organisation for Economic Co-Operation and Development and the PRODEO Institute, Paris, France.
Jeffrey CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas (UNLV), Henderson, NV, USA.
Francois VeronNewfund Capital, Paris, France.
Vicki ZikopoulouLikeminds, Boston, MA, USA.
Agustin IbanezGlobal Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA.
Kacie KellyNeuroscience-Inspired Policy Initiative, Organisation for Economic Co-Operation and Development and the PRODEO Institute, Paris, France.
Jair C SoaresDepartment of Psychiatry, University of Texas Health Sciences Center at Houston, Houston, TX, USA.
Erin SmithNeuroscience-Inspired Policy Initiative, Organisation for Economic Co-Operation and Development and the PRODEO Institute, Paris, France.
Barnabas J GilbertSchool of Medicine, Imperial College London, London, UK.

Funding

Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9M
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI Robert J. Fox, Jefferson Kinney · 2015 to 2026
$22.8M
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk FactorsU01NS093334 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CUMMINGS, JEFFREY L., REIMAN, ERIC MICHAEL · 2016 to 2022
$17.0M
NVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI FOX, ROBERT J. · 2020 to 2022
$3.3M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
NIA NIH HHS P20 AG068053NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG053798NIA NIH HHS R35 AG071476NIGMS NIH HHS P20 GM109025NINDS NIH HHS U01 NS093334
6 · The paper itself

Abstract

With the exponential growth in investment attention to brain health-solutions spanning brain wellness to mental health to neurological disorders-tech giants, payers, and biotechnology companies have been making forays into this field to identify technology solutions and pharmaceutical amplifiers. So far, their investments have had mixed results. The concept of open innovation (OI) was first coined by Henry Chesbrough to describe the paradigm by which enterprises allow free flow of ideas, products, and services from the outside to the inside and vice versa in order to remain competitive, particularly in rapidly evolving fields where there is abundant, relevant knowledge outside the traditional walls of the enterprise. In this article, we advocate for further exploration and advancement of OI in brain health.

Indexed as

BrainHumansInventionsMental Healthbrain healthclosed innovationcorporate innovationentrepreneurshipequityOpen innovationventure capital

Identifiers

PMID35904045
PMCPMC9906564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.